Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 6/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12215159 | 0.93 | PTGS2 (0.55) | PTGS2CYP3A4CNR1CNR2MEN1 | |
| SCHEMBL12215160 | 0.93 | PTGS2 (0.55) | PTGS2CYP3A4CNR1CNR2MEN1 | |
| SCHEMBL10141517 | 0.88 | PTGS2 (0.50) | PTGS2CYP3A4ACHECNR1CNR2 | |
| SCHEMBL10141520 | 0.88 | PTGS2 (0.50) | PTGS2CYP3A4ACHECNR1CNR2 | |
| SCHEMBL19323300 | 0.83 | PLA2G2A (0.54) | — | |
| SCHEMBL9479894 | 0.82 | PLA2G4B (0.47) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL3844534 | 0.81 | MEN1 (0.47) | PTGS2CYP3A4ACHEMEN1THRB | |
| SCHEMBL4598914 | 0.81 | MEN1 (0.47) | PTGS2CYP3A4ACHEMEN1THRB | |
| SCHEMBL10427861 | 0.81 | MEN1 (0.47) | PTGS2CYP3A4ACHEMEN1THRB | |
| SCHEMBL9281683 | 0.81 | MEN1 (0.47) | PTGS2CYP3A4ACHEMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9798235-B2 | Positive type resist composition for use in liquid immersion exposure and a method of forming the pattern using the same | FUJIFILM CORPORATION (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20170255098-A1 | POSITIVE TYPE RESIST COMPOSITION FOR USE IN LIQUID IMMERSION EXPOSURE AND A METHOD OF FORMING THE PATTERN USING THE SAME | FUJIFILM CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
| US-9703196-B2 | Positive type resist composition for use in liquid immersion exposure and a method of forming the pattern using the same | FUJIFILM CORPORATION (JP) | 2017-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170255098-A1 | POSITIVE TYPE RESIST COMPOSITION FOR USE IN LIQUID IMMERSION EXPOSURE AND A METHOD OF FORMING THE PATTERN USING THE SAME | POLR2H, POLQ, RXRA | PTGS2 2890/4885CYP3A4 4654/4885ACHE 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.